ASTHMA

Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial

B P A Thoonen, T R J Schermer, G van den Boom, J Molema, H Folgering, R P Akkermans, R Grol, C van Weel, C P van Schayck

Background: A study was undertaken to determine the effectiveness of asthma self-management in general practice.

Methods: Nineteen general practices were randomly allocated to usual care (UC) or self-management (SM). Asthma patients were included after confirmation of the GP diagnosis. Follow up was 2 years. Patients kept diary cards and visited the lung function laboratory every 6 months. Outcomes were number of successfully treated weeks, limited activity days, asthma specific quality of life, forced expiratory volume in 1 second (FEV1), reversibility of FEV1, concentration of histamine provoking a fall in FEV1 of 20% or more (PC20 histamine), and amount of inhaled steroids.

Results: A total of 214 patients were included in the study (104 UC/110 SM; one third of the total asthma population in general practice); 62% were female. The mean percentage of successfully treated weeks per patient in the UC group was 72% (74/103 weeks) compared with 78% (81/105 weeks) in the SM group (p=0.003). The mean number of limited activity days was 1.2 (95% CI 0.5 to 1.9) in the SM group and 3.9 (95% CI 2.5 to 5.4) in the UC group. The estimated increase in asthma quality of life score was 0.10 points per visit in the UC group and 0.21 points per visit in the SM group (p=0.055). FEV1, FEV1 reversibility, and PC20 histamine did not change. There was a saving of 217 puffs of inhaled steroid per patient in favour of the SM group (p=0.05).

Conclusion: Self-management lowers the burden of illness as perceived by patients with asthma and is at least as effective as the treatment usually provided in Dutch primary care. Self-management is a safe basis for intermittent treatment with inhaled corticosteroids.

Asthma is a chronic inflammatory pulmonary disease which has a significant socioeconomic impact on patients and their families. The finding that airway inflammation is the key underlying process in asthma has led to recommendations that inhaled corticosteroids should be introduced early in the management of the disease. Despite these guidelines and increasing knowledge, asthma morbidity is still considerable. Poor compliance with prescribed inhaled treatment is an important cause of uncontrolled disease. Poor control of asthma is associated with an impaired quality of life and is calculated to be responsible for three quarters of the total costs of asthma. It is therefore likely that improving compliance with treatment will lead to improvements in asthma control and quality of life. Low compliance results in underuse of medication, but asthma is also characterised by overuse, particularly of inhaled medication. Overuse of inhaled steroids may increase the number of unwanted side effects without additional benefits. There are indications that inhaled steroids can be tapered off or stopped during certain periods, or at least reduced to the minimal effective daily dose that provides adequate control of the disease. Optimising treatment for the individual patient may balance benefits and risks and lead to a more efficient and cost effective treatment.

Patients with mild asthma treated by their general practitioner (GP) may be suitable for intermittent treatment, providing adequate control of their asthma is maintained. Implementing guided self-management takes a considerable effort and studies on effectiveness and use in general practice are needed. Most published studies have shown self-management to be effective in patients with more severe asthma or those with frequent exacerbations, and it is unknown whether guided self-management may also be effective in patients with milder asthma. Loss of asthma control occurs less frequently and there is lower impact on quality of life, leaving limited room for improvement. The aim of this study was to determine if guided self-management can provide a safe treatment strategy for asthmatic patients in general practice.

METHODS

Practices

General practices were recruited from two pools; the first were in and around the city of Eindhoven and the second were practices from our department’s academic research network. Recruitment was stopped when a sufficient number of participating practices was reached. Practices rather than individual patients were randomised to prevent contamination. To prevent management bias, stratified cluster randomisation was performed based on the type of practice (one GP, two GPs, group practice), the number of identified asthmatics (above or below the median number (14) of identified patients), and use of computerised prescriptions (yes, no).

Selection of patients

GPs identified all asthma patients aged between 16 and 60 years using problem list coding (ICPC), prescription data from practice records, the annual influenza vaccination campaign list, and prescription data provided by the local pharmacist. Identified patients received an invitation letter from their GP to participate in the study. Patients willing to participate were invited for assessment in a lung function laboratory. Inclusion and exclusion criteria are summarised in box 1. Inclusion criteria were measured for all patients without exclusion criteria. Patients with a pre-bronchodilator forced expiratory volume in 1 second (FEV1) of <80% predicted were treated with 800 μg budesonide twice daily during a 6 week run in period
Box 1 Inclusion and exclusion criteria

Exclusion criteria
- Smoking history of 15 or more pack years
- Serious diseases other than asthma with a low survival rate
- Exacerbations during the month before the start of the study
- Other diseases which influence bronchial symptoms and/or lung function such as heart failure, sarcoidosis
- Inability to inhale medication correctly or to measure and record peak flow adequately and unlikely that this can be taught

Inclusion criteria
- Treated for asthma by the GP and
- Age 16–60 years and
- FEV₁ <40% of predicted value and >55% of predicted value 15 minutes after inhalation of 800 µg salbutamol or 6 weeks after inhalation of 800 µg budesonide twice daily and
- FEV₁ reversibility (after bronchodilation with 800 µg salbutamol metered dose inhaler or 8 weeks treatment with 800 µg budesonide twice daily) of at least 10% of the predicted value or PC₂₀ histamine of 8 mg/ml.

Box 2 Summary of self-treatment plan

Step-up instructions
- Peak flow deteriorates <80%, peak expiratory flow rate (PEFR) >60% of personal best value (PBV) for 2 out of 3 consecutive days:
  - double budesonide dosage;
  - in case of insufficient response within 3 weeks. again double budesonide dosage.
- Peak flow deteriorates <60%, PEFR >40% of PBV for 2 out of 3 consecutive days:
  - increase budesonide dosage to 800 µg twice daily;
  - in case of insufficient response within 2 days, start course of oral prednisolone
  - and contact your GP.
- Peak flow deteriorates <40% of PBV:
  - if sufficient response to bronchodilator, start course of oral prednisolone;
  - Otherwise, immediately contact your GP.

Step-down instructions
- Peak flow improves to ≥40%, PEFR <60% of PBV:
  - continue the current budesonide dosage until PEFR is ≥80% of PBV.
- Peak flow improves to ≥60%, PEFR <80% PBV:
  - continue the current budesonide dosage until PEFR is ≥80% of PBV.
- Peak flow improves to ≥80% of PBV:
  - halve budesonide dosage when PEFR ≥80% for a period of 6 weeks.

Self-management programme

The self-management (SM) programme started with four individual training visits of 30, 20, and 2 × 10 minutes, respectively, at the GP’s surgery during a period of 3 months. These visits consisted of tailored education and instructions on how to use a personalised written self-treatment plan. Patients weekly recorded morning and evening peak flow values and the presence of asthma symptoms. Three alarm symptoms were defined: waking at night because of asthma (yellow zone), use of bronchodilator >4 times a day (red zone), and increased dyspnoea without exertion (purple zone). In the presence of alarm symptoms or a fall in peak flow values below 80%, 60%, or 40% of the personal best value, patients were instructed to start daily measurements of peak flow and symptoms. Self-treatment instructions for budesonide and oral steroids (30 mg prednisolone per day for 1 week) are summarised in box 2. After the training visits biannual control visits were recommended over a follow up period of 21 months. At each control visit (10 minutes) GPs checked the patients’ performance of the self-treatment instructions. It was left to the initiative of the GP and patient if and when these control visits took place. Training in the inhalation technique and peak flow measurement was repeated at each visit.

Usual care

In the usual care (UC) group GPs were instructed to treat all asthma patients as usual; for most GPs this is according to the national guidelines for treatment of asthma. Both groups received regular inhalation instructions.

Outcome measures

The main outcome measures of the study were asthma control, asthma specific quality of life, and lost activity days. Asthma control was defined using the following parameters:
- percentage of successfully treated weeks;
- changes in post-bronchodilator FEV₁ (800 µg salbutamol once daily through spacer);
- changes in reversibility of FEV₁, as percentage of the predicted value; and
- changes in concentration of histamine provoking a fall in FEV₁, of 20% or more (PC₂₀ histamine).

Patients visited the lung function laboratory every 6 months over a period of 2 years. Diary cards were collected and checked for errors. At each visit post-bronchodilator FEV₁, reversibility, and asthma specific quality of life were measured. PC₂₀ histamine was measured at baseline and after 2 years. Assessors were not blinded to study group allocation.

Step-up instructions

A successfully treated week was defined as a week in which acceptable asthma control in terms of perceived dyspnoea was maintained. Patients in both groups weekly recorded dyspnoea on a modified Borg scale ranging from 0 (no dyspnoea) to 10 (maximally severe dyspnoea). The median dyspnoea score of all individual recordings was considered as the cut off point between successfully and unsuccessfully treated weeks. Weeks with a dyspnoea score equal to or below this cut off point were counted as successful. Successfully treated weeks were calculated if patients had recorded at least 52 weeks. To correct for differences in the number of recorded weeks, successfully treated weeks were standardised to the percentage of recorded weeks. An example of this procedure is summarised graphically for one patient in fig 1. In addition to the dyspnoea scores, patients weekly recorded the number of days during the previous week with limited activities due to asthma.

Asthma specific quality of life was measured using the Asthma Quality of Life Questionnaire (AQLQ) developed by Juniper et al. An individual increase of 0.5 points on the
observed standard deviation of 0.9, a power of 90% and an interclass correlation of 0.02. With an analysis, we assumed an average inclusion of 10 patients per practice and an interclass correlation of 0.02. Based on multilevel analysis, we assumed an average inclusion of 10 patients per practice and an interclass correlation of 0.02. With an observed standard deviation of 0.9, a power of 90% and an α of 0.05 (two sided), 17 practices with a total number of 170 patients were needed. After taking into account a drop out rate of 20%, it was calculated that 213 patients were needed.

**Analysis of data**

Outcome parameters were evaluated on an intention to treat basis and by repeated measurement techniques. A random coefficient linear model (multilevel) with an autoregressive error structure was performed on post-bronchodilator FEV₁ and AQLQ scores. Reversibility of FEV₁ (% predicted value) was analysed in a similar non-linear model. Baseline values, age, sex, and smoking were entered as possible confounders. All analyses were performed using the PROC MIXED procedures by SAS. Transformed PC<sub>20</sub> values (log PC<sub>20</sub>) were compared with a Student’s t test. If there was a significant difference over time in any quality of life domain, the proportions of subjects with a relevant change over 2 years (MCID) were compared using χ<sup>2</sup> tests. The amounts of medication used in both groups and the percentages of successfully treated weeks were compared using a t test when normally distributed and a Mann-Whitney U test when not normally distributed.

**RESULTS**

Of 38 practices invited to participate in the study, 19 agreed to do so. Table 1 shows the characteristics of the participating practices in both treatment groups. The flow chart in fig 2 summarises the number of patients. During the pretreatment phase 15 patients dropped out of the programme and a further five dropped out before the first follow up assessment. A total of 193 patients (98 SM) were therefore included in the intention to treat analysis. The baseline characteristics of the patients included in the intention to treat analysis are shown in table 2. The treatment groups did not differ in general or clinical characteristics at baseline apart from a higher proportion of patients reporting a recent episode of aggravated asthma symptoms and lower AQLQ scores in the SM group. Fourteen patients in the SM group and 16 in the UC group did not use bronchodilator medication during the study. At baseline, long acting β<sub>2</sub> agonists were used by six patients in the SM group and by four in the UC group. During the study 12 SM and five UC patients used a long acting β<sub>2</sub> agonist; theophyllines were used by three patients in the SM group.

Successfully treated weeks could be calculated for 83 (85%) and 87 (92%) subjects in the SM and UC groups, respectively. The mean percentage of successfully treated weeks per patient in the SM group was 78% (95% CI 75.1 to 80.6) (81/105) recorded weeks compared with 72% (95% CI 68.8 to 74.8) (74/103) recorded weeks in the UC group. During follow up 79% of SM and 62% of UC patients reported one or more limited activity days. When all patients were included, the mean number of limited activity days was 1.9 (95% CI 0.7 to 3.2) for the SM group and 6.0 (95% CI 2.6 to 9.4) for the UC group. Closer examination identified two distinct outliers in the UC group with 142 limited activity days and 69 limited activity days, respectively. One of the outliers

---

**Table 1** Characteristics of participating practices

<table>
<thead>
<tr>
<th></th>
<th>Self-management</th>
<th>Usual care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of practices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 GP</td>
<td>2 (25%)</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>2 GPs</td>
<td>3 (37%)</td>
<td>5 (46%)</td>
</tr>
<tr>
<td>&gt;2 GPs</td>
<td>3 (38%)</td>
<td>5 (45%)</td>
</tr>
<tr>
<td>Total</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>No (95% CI) of asthmatics per 1000 patients</td>
<td>7.6 (5.6 to 9.6)</td>
<td>9.0 (4.9 to 13.2)</td>
</tr>
<tr>
<td>Computerised prescription</td>
<td>Yes/no</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7/1</td>
<td>8/3</td>
</tr>
</tbody>
</table>

---

**Figure 1** Calculation of successfully treated weeks for one patient in the usual care group. Number of registered weeks = 104; median dyspnoea score = 3; number of weeks with dyspnoea ≤ median dyspnoea score = 64; percentage of successfully treated weeks = (64/104) × 100 = 61.5%.

---
had a period of several months with frequent but short episodes of sick leave due to asthma, the other a 3 month episode of uninterrupted sick leave. In both cases irritant exposure in the workplace explained the high counts. Because of the clear work related cause and the disproportionate impact of these two outliers on the group mean, we decided to exclude subjects above the 98th percentile from the final calculations in both groups. This resulted in a mean number of limited activity days of 1.2 (95% CI 0.5 to 1.9) for the SM group and 3.9 (95% CI 2.5 to 5.4) for the UC group.

**Figure 2** Flow chart showing study participants.

[Flow chart showing study participants]

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Baseline characteristics of study subjects included in the intention to treat analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Self-management (n=98)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>39.6 (11.2)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>34/64</td>
</tr>
<tr>
<td>Smoking:</td>
<td></td>
</tr>
<tr>
<td>Never smokers</td>
<td>45 (46%)</td>
</tr>
<tr>
<td>Former smokers</td>
<td>31 (32%)</td>
</tr>
<tr>
<td>Current smokers</td>
<td>22 (22%)</td>
</tr>
<tr>
<td>Pack years*</td>
<td>5.8 (4.5)</td>
</tr>
<tr>
<td>% requiring pretreatment with budesonide†</td>
<td>34 (35%)</td>
</tr>
<tr>
<td>% with asthma attack(s) in previous 6 months</td>
<td>48.5%</td>
</tr>
<tr>
<td>FEV₁ (% predicted value):</td>
<td></td>
</tr>
<tr>
<td>Pre-bronchodilator (BD)**</td>
<td>84.0 (13.1)</td>
</tr>
<tr>
<td>Post-bronchodilator (BD)</td>
<td>90.0 (12.1)</td>
</tr>
<tr>
<td>FEV₁ reversibility (%) (median‡ **</td>
<td>5.0 (8.6) IQR 5.4 (6.8) IQR</td>
</tr>
<tr>
<td>Bronchial hyperresponsiveness</td>
<td></td>
</tr>
<tr>
<td>PC₂₀ geometric mean</td>
<td>1.20</td>
</tr>
<tr>
<td>Initial dose of inhaled steroids</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>12 (12%)</td>
</tr>
<tr>
<td>Low (&lt;400 µg daily or equivalent)</td>
<td>36 (37%)</td>
</tr>
<tr>
<td>Intermediate (&gt;400 and &lt;800 µg daily or equivalent)</td>
<td>34 (35%)</td>
</tr>
<tr>
<td>High (&gt;800 µg daily or equivalent)</td>
<td>16 (16%)</td>
</tr>
<tr>
<td>Quality of life:</td>
<td></td>
</tr>
<tr>
<td>Activities domain</td>
<td>5.3 (1.03)</td>
</tr>
<tr>
<td>Emotions domain</td>
<td>5.8 (1.01)</td>
</tr>
<tr>
<td>Symptoms domain</td>
<td>5.3 (1.03)</td>
</tr>
<tr>
<td>Environment domain</td>
<td>5.3 (1.10)</td>
</tr>
<tr>
<td>Overall score</td>
<td>5.4 (0.872)</td>
</tr>
</tbody>
</table>

Figures are mean (SD) values unless stated otherwise.
FEV₁=forced expiratory volume in 1 second in litres; FVC=forced vital capacity.
*Missing data (self-management 2, usual care 1); †missing data (self-management 2, usual care 2); ‡pretreatment consisted of 6 weeks budesonide 800 µg twice daily; §difference between FEV₁ before and after bronchodilator/predicted FEV₁.
Mean budesonide usage was 1680 puffs per patient (95% CI 1538 to 1822) in the SM group and 1897 puffs per patient (95% CI 1679 to 2115) in the UC group, indicating a saving of 217 puffs per patient.

With a median (IQR) dose of 97 (168) µg/day of short-acting β2 bronchodilators in the SM group and 69 (340) µg/day in the UC group, there was no statistically significant difference between the two study groups \( (p=0.711, \text{Mann-Whitney U test}) \). In the SM group a median (IQR) dose of 12 (28) µg/day of ipratropium was used compared with 35 (114) µg/day in the UC group \( (p=0.607, \text{Mann-Whitney U test}) \).

Table 3 summarises the indicators of exacerbations. There were no differences in the number of GP diagnosed exacerbations and the number of antibiotics between the two groups, but the SM group had a significantly higher number of courses of oral prednisolone than the UC group \( (p=0.015, \text{Mann-Whitney U test}) \).

**DISCUSSION**

Findings from this study indicate that asthma control improved in the SM group in terms of a higher number of successfully treated weeks and fewer limited activity days. There were no major changes in lung function parameters. In the SM group there was a slight improvement in asthma specific quality of life with a clinically relevant improvement in the emotions domain, indicating that patients in this group felt less worried or insecure about the influence of their asthma on daily life. GPs did not diagnose more exacerbations, but the number of oral prednisolone courses was higher in the guided SM group. The study population consisted of approximately one third of all subjects initially identified by GPs. Determinants of willingness to participate and their implications have been discussed extensively elsewhere. The main implication is that subjects with low or intermediate doses of inhaled corticosteroids at baseline may have been relatively over-represented in this study. Based on initial levels of pred- and post-bronchodilator FEV1, the observed reversibility and initial dosage of inhaled steroids, included patients appeared approximately one third of all subjects initially identified by GPs. Determinants of willingness to participate and their implications have been discussed extensively elsewhere. The main implication is that subjects with low or intermediate doses of inhaled corticosteroids at baseline may have been relatively over-represented in this study. Based on initial levels of pre-

Half of all invited practices participated in this study, which does not differ from previously studied acceptance rates. Other practice characteristics (table 1) also suggest that participating practices were a representative sample of Dutch general practice, with the restriction that participants have a positive attitude towards self-management.

There have been few randomised controlled trials to date on the effects of guided self-management programmes in family...
During the study long acting β agonists were introduced in updated Dutch guidelines on diagnosis and treatment of asthma. Treatment with long acting β agonists was initiated in a relatively higher proportion of patients in the SM group but numbers were too small to allow for reliable statistics. It is therefore unlikely that prescription of long acting β agonists substantially contributed to improvements in successfully treated weeks or quality of life in favour of the SM group.

Based on our findings, we conclude that self-management of asthma is at least equally effective as asthma treatment usually provided in Dutch primary care. Asthma self-management provides a safe basis for intermittent treatment with inhaled corticosteroids and lowers the burden of illness as perceived by patients. Observed patient related outcomes are those in which self-management distinguishes itself from usual asthma care, even under conditions where room for improvement initially seemed limited.

Authors’ affiliations
B A Thoonen, T R J Schermer, G van den Boom, R P Akkermans, C van Weel, C P van Schayck*, Department of General Practice/Family Medicine, University Medical Centre Nijmegen, The Netherlands
Barnel, H Folgering, University Lung Centre Dekkerswald, University Medical Centre Nijmegen, The Netherlands
R Grof, Centre for Quality of Care Research, University of Maastricht and University Medical Centre Nijmegen, The Netherlands.

This research project has been made possible by research grants from the Netherlands Organization for Scientific Research (NWO) and ASTRAZeneca Pharmaceutica BV.

Conflicts of interest: none.

REFERENCES
10 Horn CR, Clark TJ, Cochrane GM. Compliance with inhaled therapy and morbidity from asthma. Respir Med 1990;84:67–70.

*Present address: Department of General Practice/Family Medicine, University of Maastricht, The Netherlands.


24 Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42:697–705.


LUNG ALERT

Decreases in air pollutants may lead to lower cardiopulmonary mortality

Air pollution, deaths, and the weather were compared for 72 months before and 72 months after the ban on coal sales in the city of Dublin on 1 September 1990. This led to a fall in black smoke of 35.6 µg/m³ (70%) and a fall in sulphur dioxide levels of 33%. Age-standardised death rates were adjusted to the 1991 Irish census population. Cardiovascular deaths accounted for 45% and respiratory deaths for 15% of non-trauma deaths. Total non-trauma deaths fell by 5.7%, cardiovascular deaths by 10.3%, and respiratory deaths by 15.5% (p<0.001 in all cases). This amounted to 243 fewer cardiovascular deaths and 116 fewer respiratory deaths per year after the ban.

This study shows substantially larger effect estimates compared with the effect sizes from daily time series mortality studies, strongly suggesting a long term cumulative effect of air pollution exposure.

A Bhowmik
angshub@altavista.net
Self-management of asthma in general practice, asthma control and quality of life: a randomised controlled trial

B P A Thoonen, T R J Schermer, G van den Boom, J Molema, H Folgering, R P Akkermans, R Grol, C van Weel and C P van Schayck

Thorax 2003 58: 30-36
doi: 10.1136/thorax.58.1.30